2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Nicole Concin, MD, discusses the patient population that enrolled in the phase 1b/2 LIO-1 trial in advanced gynecologic malignancies.
Nicole Concin, MD, professor, experimental gynecology, Department of Gynecology and Obstetrics, Medical University of Innsbruck, Innsbruck, Austria, discusses the patient population that enrolled in the phase 1b/2 LIO-1 trial in advanced gynecologic malignancies.
The phase 2 portion of the LIO-1 trial will enroll approximately 161 patients with advanced, recurrent, or metastatic gynecological malignancies, Concin says.
Four cohorts will be included in the study: endometrial cancer, cervical cancer, ovarian cancer excluding clear-cell histology, and clear-cell ovarian/endometrial cancer.
Clear-cell gynecologic carcinoma is a rare disease, so the inclusion of this subtype is a unique feature of the study, explains Concin.
The LIO-1 trial will evaluate the safety and efficacy of the investigational TKI lucitanib and nivolumab (Opdivo) in this patient population.